These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9109333)

  • 21. Effect of latanoprost 0.005% and brimonidine 0.2% on intraocular pressure after phacoemulsification and intraocular lens implantation surgery.
    Erdogan H; Toker MI; Arici MK; Topalkara A
    Jpn J Ophthalmol; 2004; 48(6):600-1. PubMed ID: 15592790
    [No Abstract]   [Full Text] [Related]  

  • 22. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
    Chevrier RL; Assalian A; Duperré J; Lesk MR
    Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the intraocular pressure-reducing effect of latanoprost as monotherapy in open-angle glaucoma.
    Mandić Z; Bojić L; Novak-Laus K; Sarić D
    Coll Antropol; 2002 Dec; 26(2):595-600. PubMed ID: 12528287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
    Titouamane S; Baudouin C
    J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Miotic effect of alphagan P.
    Faulkner W
    J Cataract Refract Surg; 2003 Mar; 29(3):423. PubMed ID: 12662989
    [No Abstract]   [Full Text] [Related]  

  • 27. Brimonidine and pupillary diameter.
    Mastropasqua L; Carpineto P; Ciancaglini M
    Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
    [No Abstract]   [Full Text] [Related]  

  • 28. How I choose a prostaglandin analogue.
    Alward WL
    Am J Ophthalmol; 2009 Jan; 147(1):1-2. PubMed ID: 19100349
    [No Abstract]   [Full Text] [Related]  

  • 29. [Current trend of glaucoma medication with various eye drops].
    Fukuchi T
    Nippon Ganka Gakkai Zasshi; 2013 Oct; 117(10):781-3. PubMed ID: 24354261
    [No Abstract]   [Full Text] [Related]  

  • 30. New agents in glaucoma therapy.
    Kooner KS
    Int Ophthalmol Clin; 1999; 39(3):1-15. PubMed ID: 10709570
    [No Abstract]   [Full Text] [Related]  

  • 31. The diagnosis and adrenergic therapy of open-angle glaucoma.
    Hart RW; Langham ME
    Isr J Med Sci; 1972; 8(8):1385-93. PubMed ID: 4405282
    [No Abstract]   [Full Text] [Related]  

  • 32. Prostaglandin analogues: a new classification of ocular hypotensive agents used in the treatment of glaucoma.
    Gallucci GM
    Nurse Pract; 1996 Nov; 21(11):144-6. PubMed ID: 8933541
    [No Abstract]   [Full Text] [Related]  

  • 33. [Glaucoma: early diagnosis is central].
    Praxis (Bern 1994); 2006 Jul; 95(27-28):2 p following 1094. PubMed ID: 16892508
    [No Abstract]   [Full Text] [Related]  

  • 34. The impact of new drugs on management of glaucoma in Scotland: observational study.
    Bateman DN; Clark R; Azuara-Blanco A; Bain M; Forrest J
    BMJ; 2001 Dec; 323(7326):1401-2. PubMed ID: 11744564
    [No Abstract]   [Full Text] [Related]  

  • 35. Inner canthus hypertrichosis: a side effect of prostaglandin analogue treatment for glaucoma.
    Monselise A; Shapiro J; Lui H
    J Cutan Med Surg; 2011; 15(5):298-9. PubMed ID: 21962192
    [No Abstract]   [Full Text] [Related]  

  • 36. New drug therapies for glaucoma.
    Bartlett JD
    J Am Optom Assoc; 1996 Nov; 67(11):648-53. PubMed ID: 8979656
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical pharmacology. Sympathetic amines.
    Macri FJ
    Eye Ear Nose Throat Mon; 1970 Nov; 49(11):510-1. PubMed ID: 4394755
    [No Abstract]   [Full Text] [Related]  

  • 38. A case of suspected alphagan-induced psychosis.
    Kim DD
    Arch Ophthalmol; 2000 Aug; 118(8):1132-3. PubMed ID: 10922214
    [No Abstract]   [Full Text] [Related]  

  • 39. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans.
    Camras CB
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():519-25. PubMed ID: 7732900
    [No Abstract]   [Full Text] [Related]  

  • 40. [Neuroprotection. Bases and possibilities of a future clinical use].
    Lagrèze WA
    Ophthalmologe; 2001 Mar; 98(3):235-6. PubMed ID: 11320808
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.